July 14, 2025 – Redeye’s analyst Richard Ramanius interviews Sofia regarding last week’s newsflow. The interview is held in Swedish.
July 9, 2025 – Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company´s projections and assumed market expectations.
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreMay 20, 2025
Oncopeptides AB today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain.
Read moreApril 16, 2025
Oncopeptides announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).
Read moreApril 1, 2025
Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
Read more
July 14, 2025
Redeye's analyst Richard Ramanius interviews Sofia regarding last week's newsflow. The interview is held in Swedish.
Read moreJuly 9, 2025
Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company´s projections and assumed market expectations.
Read more
July 8, 2025
Read more2025-07-22 - 2025-08-20
Other
2025-08-21
Report
2025-10-06 - 2025-11-04
Other
Released May 15, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q2 2025 will be published August 21, 2025
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
